#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	12862	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2056	618.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1418	1418	C	699	C,T	684,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23880	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3647	650.3	0	.	n	.	0	T695C	SNP	695	695	T	1096	1096	C	713	C	704	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23880	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3647	650.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1738	1738	A	821	A,G	789,19	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23880	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3647	650.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2372	2372	C	722	C	700	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23880	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3647	650.3	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2998	2998	T	741	T,C,A	466,260,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23880	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3647	650.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2446	2446	A	765	A,G	746,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1610	folP	852	852	100.0	folP.l15.c4.ctg.1	1528	104.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1000	1002	AGC	154;156;157	A;G;C	152;153;153	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4478	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3361	132.3	1	SNP	p	S91F	0	.	.	271	273	TCC	545	547	TCC	135;135;135	T;C,T;C	135;130,4;133	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4478	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3361	132.3	1	SNP	p	D95G	0	.	.	283	285	GAC	557	559	GAC	133;134;134	G;A,G;C	131;127,4;132	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4478	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3361	132.3	1	SNP	p	D95N	0	.	.	283	285	GAC	557	559	GAC	133;134;134	G;A,G;C	131;127,4;132	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1346	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1319	101.2	0	.	p	.	0	A39T	NONSYN	115	117	GCC	407	409	ACC	169;168;165	A,G;C;C	153,3;162;160	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1346	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1319	101.2	0	.	p	.	0	R44H	NONSYN	130	132	CGC	422	424	CAC	169;164;165	C;A,G;C	162;152,3;161	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1346	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1319	101.2	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	605	607	CAC	175;174;171	C,T;A;C	167,2;163;168	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1346	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1319	101.2	1	SNP	p	G45D	0	.	.	133	135	GGC	425	427	GGC	167;167;168	G;G;C	162;164;165	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	812	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1045	77.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4442	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2966	148.5	1	SNP	p	D86N	0	.	.	256	258	GAC	567	569	GAC	182;182;182	G;A;C	179;177;178	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4442	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2966	148.5	1	SNP	p	S87I	0	.	.	259	261	AGT	570	572	AGT	184;184;184	A,C;G;T	176,4;180;181	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4442	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2966	148.5	1	SNP	p	S87R	0	.	.	259	261	AGT	570	572	AGT	184;184;184	A,C;G;T	176,4;180;181	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4442	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2966	148.5	1	SNP	p	S87W	0	.	.	259	261	AGT	570	572	AGT	184;184;184	A,C;G;T	176,4;180;181	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4442	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2966	148.5	1	SNP	p	S88P	0	.	.	262	264	TCC	573	575	TCC	183;184;183	T;C;C	176;178;180	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3486	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2712	127.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1576	1578	GGC	179;178;176	G;G;C,A	175;171;167,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2482	132.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1367	1369	GCA	190;192;197	G,A;C;A,C	182,1;185;190,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2482	132.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1370	1372	ATC	199;200;203	A;T;C,G	193;195;196,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2482	132.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1382	1384	GTG	191;190;188	G;T;G	186;180;185	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2482	132.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1382	1384	GTG	191;190;188	G;T;G	186;180;185	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2482	132.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1886	1888	ACC	159;157;157	A;C;C	156;154;156	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2482	132.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1940	1942	GCG	151;148;148	G;C,G;G,C	138;122,2;132,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2482	132.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1940	1942	GCG	151;148;148	G;C,G;G,C	138;122,2;132,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2482	132.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2063	2065	GGC	116;117;115	G,T,A;G;C,T	111,1,1;115;107,2	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2482	132.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2072	2074	GGC	106;105;105	G,A;G;C	98,2;101;100	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2482	132.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2090	2092	CCG	86;88;88	C;C;G	82;84;79	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4830	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3141	152.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1908	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1817	103.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	578	578	C	111	C	106	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	296	porB1a	984	363	90.19	porB1a.l15.c30.ctg.2	596	20.6	0	.	p	.	0	H217N	NONSYN	649	651	CAT	122	124	AAT	16;16;16	A;A;T	16;16;15	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	296	porB1a	984	363	90.19	porB1a.l15.c30.ctg.2	596	20.6	0	.	p	.	0	D218N	NONSYN	652	654	GAT	125	127	AAT	16;15;15	A;A;T	16;15;15	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	296	porB1a	984	363	90.19	porB1a.l15.c30.ctg.2	596	20.6	0	.	p	.	0	A222V	NONSYN	664	666	GCT	137	139	GTT	15;15;15	G;T,C;T,C	15;13,2;13,2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	296	porB1a	984	363	90.19	porB1a.l15.c30.ctg.2	596	20.6	0	.	p	.	0	V226A	NONSYN	676	678	GTA	149	151	GCA	15;15;15	G;C;A	15;15;15	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	296	porB1a	984	363	90.19	porB1a.l15.c30.ctg.2	596	20.6	0	.	p	.	0	.	MULTIPLE	700	702	ACT	172	174	GTA	12;12;12	G;T;A	12;12;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	296	porB1a	984	363	90.19	porB1a.l15.c30.ctg.2	596	20.6	0	.	p	.	0	D238fs	FSHIFT	712	712	G	184	184	G	13	G	12	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2438	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1456	164.6	0	.	p	.	0	E48G	NONSYN	142	144	GAA	418	420	GGA	200;206;207	G,T;G;A	193,1;200;198	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2438	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1456	164.6	0	.	p	.	0	F135L	NONSYN	403	405	TTT	679	681	CTT	165;166;164	C,G;T;T,G	162,3;165;160,3	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2438	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1456	164.6	0	.	p	.	0	R143G	NONSYN	427	429	AGA	703	705	GGA	160;157;159	G,A,C;G,A;A	152,3,1;150,5;152	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2438	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1456	164.6	0	.	p	.	0	D171G	NONSYN	511	513	GAT	787	789	GGT	153;150;152	G;G,A;T,G	148;144,3;141,2	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2438	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1456	164.6	0	.	p	.	0	G189S	NONSYN	565	567	GGC	841	843	AGC	148;149;149	A,G;G;C	140,2;141;144	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2438	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1456	164.6	0	.	p	.	0	Y202C	NONSYN	604	606	TAC	880	882	TGC	155;154;150	T,C;G,A;C	147,1;146,4;142	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2438	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1456	164.6	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	907	907	T	151	T	145	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2438	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1456	164.6	1	SNP	p	G120K	0	.	.	358	360	GGT	634	636	GGT	179;179;181	G,A;G,A;T,C,G	174,2;177,1;170,1,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2438	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1456	164.6	1	SNP	p	A121D	0	.	.	361	363	GCC	637	639	GCC	178;175;172	G,A;C,A,G;C	174,1;171,1,1;171	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2438	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1456	164.6	1	SNP	p	A121N	0	.	.	361	363	GCC	637	639	GCC	178;175;172	G,A;C,A,G;C	174,1;171,1,1;171	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8614	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4853	176.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2041	2043	AAT	166;165;163	A,C;A;T	160,5;165;162	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1060	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	1132	92.9	1	SNP	p	V57M	1	.	.	169	171	ATG	646	648	ATG	220;222;222	A;T;G	216;217;220	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
